Stockscreener 앱 받기
31.41
4.38%
-1.44
시간 외 거래:
31.21
-0.20
-0.64%
전일 마감가:
$32.85
열려 있는:
$33.12
하루 거래량:
228.13K
Relative Volume:
0.92
시가총액:
$228.18M
수익:
$32.73M
순이익/손실:
$-19.52M
주가수익비율:
-5.6825
EPS:
-5.5275
순현금흐름:
$-24.61M
1주 성능:
-15.22%
1개월 성능:
+17.38%
6개월 성능:
+296.29%
1년 성능:
+51.72%
1일 변동 폭
$30.75
$33.40
1주일 범위
$23.80
$41.50
52주 변동 폭
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
명칭
Cue Biopharma Inc
전화
617-949-2680
주소
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
31.41 | 228.18M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-13 | 개시 | Jefferies | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2022-11-21 | 개시 | Piper Sandler | Overweight |
| 2022-01-13 | 개시 | H.C. Wainwright | Buy |
| 2022-01-03 | 개시 | Craig Hallum | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-04-09 | 개시 | Stifel | Buy |
| 2020-01-28 | 개시 | BTIG Research | Buy |
| 2020-01-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Cue Biopharma Inc 주식(CUE)의 최신 뉴스
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? - Insider Monkey
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CUE) 2026-09-24 - Seeking Alpha
Cue Biopharma (CUE) Short Interest & Short Float | Updated Sep 2026 $CUE - MarketBeat
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
China syndrome? Phase II wins for Cue in CSU, stock melts down - BioWorld News
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking - AD HOC NEWS
Cue Biopharma rated Buy after positive phase 2 results show superior efficacy in treating chronic spontaneous urticaria. - Pluang
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA - Seeking Alpha
B. Riley's Buy Rating on Cue Biopharma (CUE) Highlights Market's High Price-to-Sales Expectations - GuruFocus
Cue Biopharma Announces Positive Phase 2 Results for CUE-221 in Chronic Spontaneous Urticaria - Kalkine Media
Cue Biopharma (CUE) Shares Drop 31% After Phase 2 Trial Results Despite Promising Efficacy - GuruFocus
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset - Seeking Alpha
What's Going on With Cue Biopharma Stock on Monday? - Benzinga
Cue Biopharma (CUE) Surges 41.7% Pre-Market Amid Market Rally an - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cue Biopharma reports positive Phase 2 topline results for CUE-221 in CSU, durable benefit vs placebo and omalizumab - TradingView
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results - Yahoo Finance
Why is Cue Biopharma stock surging today? By Investing.com - Investing.com Canada
Cue Biopharma, Inc.(NasdaqCM: CUE) added to S&P Global BMI Index - marketscreener.com
Cue Biopharma (CUE) Reports Positive Phase 2 Data, Market Pricin - GuruFocus
Cue Biopharma reports positive phase 2 results for CUE-221 By Investing.com - Investing.com Canada
Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria - quiverquant.com
Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria - TradingView
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) - Eastern Progress
Cue Biopharma (CUE) Stock Gains on B. Riley Buy Rating Amid High P/S Valuation - gurufocus.com
Cue Biopharma is a new Buy at B. Riley on valuation - TradingView
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
CUE Initiated Coverage On by B. Riley Securities -- Price Target $83.00 - GuruFocus
Cue Biopharma Price Target Announced at $83.00/Share by B. Riley Securities - Moomoo
Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential - Investing.com Nigeria
Enterprise value to EBIT forward of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma (CUE) Slides 8.21% to $28.00, Testing Support Near $26.60Volatility Skew - dars.gov.et
Cue Biopharma Inc (CUE) Financials FY2025: Revenue $27.5M, Net Loss $26.6M - Stock Titan
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - manilatimes.net
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Canada
Cue Biopharma Inc (CUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):